Artelo Biosciences has regained compliance with Nasdaq listing requirements for stockholders' equity and annual meeting rules, but will be subject to a one-year mandatory panel monitor through April 2027.
Key takeaways
The company received Nasdaq confirmation on April 6, 2026 that it has regained compliance with Listing Rules 5550(b)(1) and 5620(a).
Artelo will be subject to a mandatory panel monitor through April 6, 2027 under Nasdaq Listing Rule 5815(d)(4)(B).
If the company falls out of compliance with the Equity Rule during the monitoring period, Nasdaq staff will issue a Delist Determination Letter without granting additional cure time.
The company held its reconvened annual meeting on January 30, 2026 and regained compliance with the Equity Rule as of March 30, 2026.
Management stated the company remains focused on portfolio execution and potential partnership negotiations for ART27.13.